Loading…
Employees: 901
Size Beijing SL Pharmaceutical (002038.SZ) is a China Health Care company (Biotechnology) with a market value of $793M, the 2785th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.15 on 6 Nov 2026.
Performance Over six months the shares fell 20.6%, against -19.2% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue fell 3.9% over the last twelve months (peer median +4.0%); the operating margin is -118.9% (peer median -24.3%).
Valuation It trades at 7.6× enterprise value to sales against a peer median of 6.6× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is -11%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.6 points below its cost of capital (5.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥556M | CN¥622M | CN¥658M | CN¥1.01B | CN¥1.05B |
| Revenue growth | — | -5% | -35% | -4% | — |
| Gross profit | CN¥347M | CN¥241M | CN¥315M | CN¥703M | CN¥803M |
| EBITDA | n/a | -CN¥462M | CN¥175M | CN¥357M | CN¥258M |
| Net income | -CN¥838M | -CN¥347M | -CN¥74.1M | CN¥417M | CN¥234M |
| Free cash flow | CN¥551M | CN¥111M | -CN¥88.2M | CN¥275M | CN¥260M |
| Capital expenditure | CN¥56.9M | CN¥193M | CN¥347M | CN¥218M | CN¥163M |
| Total debt | CN¥21.4M | CN¥26.0M | CN¥1.26M | CN¥37.6M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002038.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | -9.0% | 11th highest of 21 |
| 6-month return | -20.6% | -19.2% | 10th lowest of 20 |
| Distance from 52-week high | -45.2% | -43.9% | 9th lowest of 21 |
| Revenue growth (TTM) | -3.9% | +4.0% | 7th lowest of 17 |
| Operating margin | -118.9% | -24.3% | 5th lowest of 18 |
| EV / Sales | 7.6× | 6.6× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -12.3% | 20.1% | least demanding of 6 |
| Growth delivered (Del g) | -10.9% | +14.7% | lowest of 6 |
| Hurdle (Req g minus delivered) | -1.4 pp | +8.3 pp | 2nd least demanding of 6 |
| ROIC minus cost of capital | -16.6 pp | -14.3 pp | 7th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |